Powered by passion. Driven by patient care. Corporate Presentation Disclaimer This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our anticipated financial results of the fiscal quarter and full year ended December 31, 2024; our commerc ...

Core Insights - The article discusses the investment position of SCPH, indicating a beneficial long position in the shares of the company [1] Group 1 - The analyst expresses personal opinions regarding SCPH and clarifies that no compensation is received for the article, aside from Seeking Alpha [1] - There is an emphasis on the importance of conducting due diligence and consulting with investment professionals before making trades [2] - The article highlights that past performance is not indicative of future results, and opinions expressed may not reflect the views of Seeking Alpha as a whole [3]

Financial Data and Key Metrics Changes - The company has seen significant growth in its integrated delivery network (IDN) sales, which were up 12 times from 2024 to 2023, indicating a strong market acceptance of its product [21] - The redesign of Medicare Part D is expected to provide a significant tailwind, with patients now having a $2,000 cap on out-of-pocket expenses, which is anticipated to drive higher fill rates and net sales [42][45] Business Line Data and Key Metrics Changes - The company’s product, Furosex, is designed to deliver 100% bioavailable furosemide, which is equivalent to the IV treatment in hospitals, allowing patients to manage their condition at home [6][14] - The approval for chronic kidney disease (CKD) indication is expected to expand the total addressable market (TAM), with approximately 700,000 patients having CKD without heart failure, and many patients suffering from both conditions [27][29] Market Data and Key Metrics Changes - The company is focusing on integrated delivery networks (IDNs) where physicians are financially aligned with hospitals, which enhances the value proposition of Furosex [19] - There is a noted difference in how various IDNs operate, with larger systems like Kaiser and the VA being more closed and structured, while smaller IDNs may require tailored protocols for best practices [25][26] Company Strategy and Development Direction - The company aims to capture the value proposition of its product by focusing on early intervention in heart failure patients to prevent hospitalizations [10][17] - The introduction of an auto-injector is expected to simplify the treatment process, reduce costs of goods sold (COGS) by 70%, and extend intellectual property protection until 2040 [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the impact of the Medicare redesign, which is expected to facilitate patient access to the drug and drive sales growth [39][46] - The expansion of the sales force is anticipated to take time to show results, but early indicators suggest positive trends in sales as more representatives engage with healthcare providers [54] Other Important Information - The company has developed internal protocols for IDNs to share best practices, which is crucial for smaller networks that may lack established guidelines [24][26] - The management highlighted the importance of addressing the needs of patients who are discharged from hospitals with residual congestion, as this presents an opportunity for Furosex to prevent readmissions [15][17] Q&A Session Summary Question: How does the company see the balance between preventing hospitalizations and reducing length of stay? - The company aims to intervene early when patients first show signs of worsening heart failure, thus preventing the need for hospitalization [10][11] Question: Are hospitals with higher readmission rates embracing Furosex? - There is a need for education among hospital staff, particularly among cardiologists who may not be fully aware of the benefits of Furosex [18] Question: How does the CKD indication expand opportunities? - The CKD indication opens up a new market segment, particularly for patients with cardiorenal disease, which is expected to drive growth [27][29] Question: What are the expected impacts of the Medicare Part D redesign? - The redesign is anticipated to lower out-of-pocket costs for patients, thereby increasing fill rates and driving sales growth [39][45] Question: How does the auto-injector fit into the company's strategy? - The auto-injector is expected to simplify the treatment process and significantly reduce costs, while also appealing to a broader patient base [49][51]

Company Performance - ScPharmaceuticals reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -25.93% [1] - The company posted revenues of $11.75 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.67%, compared to revenues of $6.1 million a year ago [2] - Over the last four quarters, ScPharmaceuticals has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - ScPharmaceuticals shares have declined approximately 34.5% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $16.95 million, and for the current fiscal year, it is -$1.03 on revenues of $76.42 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ScPharmaceuticals belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ScPharmaceuticals' stock performance [5][6]

scPharmaceuticals (SCPH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants John Tucker - President & CEOSteve Parsons - Senior Vice President of CommercialRachael Nokes - Chief Financial OfficerDouglas Tsao - Managing Director Conference Call Participants William Thorp - AnalystRoanna Ruiz - Senior Research AnalystStacy Ku - AnalystChase Knickerbocker - Senior Equity Research Analyst - Healthcare Operator a reminder, today's conference call is being recorded. I would now like to turn the c ...

scPharmaceuticals (SCPH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 a reminder, today's conference call is being recorded. I would now like to turn the conference over to Wim Thorpe, Investor Relations, to cover forward looking statements. Wim, please go ahead. Speaker1 Thank you, operator. Before beginning this afternoon's earnings call, we would like to highlight the following forward looking statements. All statements on this conference call, other than historical facts, are forward looking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of incorporation or organization) 25 Mall Road, Suite 203 01803 Burlington, Massachusetts (Zip Code) (Address of principal executive office) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcas ...

Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14th, at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceutica ...

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs. Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today annou ...